Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | hypothetical protein | 0.0507 | 0.0759 | 0.1044 |
Brugia malayi | thymidylate synthase | 0.1066 | 0.7265 | 1 |
Echinococcus multilocularis | thymidylate synthase | 0.1066 | 0.7265 | 1 |
Mycobacterium ulcerans | thymidylate synthase | 0.1066 | 0.7265 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0507 | 0.0759 | 0.5 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.1301 | 1 | 0.5 |
Schistosoma mansoni | bifunctional dihydrofolate reductase-thymidylate synthase | 0.1066 | 0.7265 | 1 |
Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.1066 | 0.7265 | 1 |
Mycobacterium leprae | PROBABLE THYMIDYLATE SYNTHASE THYA (TS) (TSASE) | 0.1066 | 0.7265 | 1 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.1301 | 1 | 0.5 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.1301 | 1 | 1 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.1301 | 1 | 0.5 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.1301 | 1 | 0.5 |
Chlamydia trachomatis | dihydrofolate reductase | 0.0442 | 0 | 0.5 |
Loa Loa (eye worm) | thymidylate synthase | 0.1066 | 0.7265 | 1 |
Onchocerca volvulus | 0.1066 | 0.7265 | 0.5 | |
Mycobacterium tuberculosis | Hypothetical protein | 0.0507 | 0.0759 | 0.1044 |
Echinococcus granulosus | thymidylate synthase | 0.1066 | 0.7265 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.